TR200103476T2 - A-beta peptide compositions and methods to prepare them - Google Patents

A-beta peptide compositions and methods to prepare them

Info

Publication number
TR200103476T2
TR200103476T2 TR2001/03476T TR200103476T TR200103476T2 TR 200103476 T2 TR200103476 T2 TR 200103476T2 TR 2001/03476 T TR2001/03476 T TR 2001/03476T TR 200103476 T TR200103476 T TR 200103476T TR 200103476 T2 TR200103476 T2 TR 200103476T2
Authority
TR
Turkey
Prior art keywords
beta peptide
methods
prepare
peptide compositions
compounds obtained
Prior art date
Application number
TR2001/03476T
Other languages
Turkish (tr)
Inventor
Hirtzer Pamela
Patel Naina
Original Assignee
Neuralab, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuralab, Ltd. filed Critical Neuralab, Ltd.
Publication of TR200103476T2 publication Critical patent/TR200103476T2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Bulus çözünebilen A beta peptid' i A beta peptid' in asiltisini içeren bilesimlere ve pH' nin çözünebilmeyi etkilemeye yetecek bir düzeye ayarlanmasiyla gerçeklestirilen bunlarin üretim yöntemlerine ve yine bunlarin steril olarak filtre edilmelerine, ayrica elde edilen bilesikler ile alzheimer hastaliginin önlenmesi ya da tedavi edilmesi için olan yöntemlere yöneliktir.In order to prevent or treat alzheimer's disease by combining the compounds obtained with the soluble A beta peptide containing the acyl of the A beta peptide and adjusting the pH to a level sufficient to affect the solubility, as well as the sterile filtering of these, and the compounds obtained. is for the methods.

TR2001/03476T 1999-06-01 2000-06-01 A-beta peptide compositions and methods to prepare them TR200103476T2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13704799P 1999-06-01 1999-06-01

Publications (1)

Publication Number Publication Date
TR200103476T2 true TR200103476T2 (en) 2002-04-22

Family

ID=22475602

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/03476T TR200103476T2 (en) 1999-06-01 2000-06-01 A-beta peptide compositions and methods to prepare them

Country Status (25)

Country Link
EP (1) EP1181040A1 (en)
JP (1) JP2003519620A (en)
KR (1) KR20020016813A (en)
CN (1) CN1353615A (en)
AR (1) AR024558A1 (en)
AU (1) AU5726100A (en)
BG (1) BG106249A (en)
BR (1) BR0011251A (en)
CA (1) CA2374897A1 (en)
CZ (1) CZ20014150A3 (en)
EE (1) EE200100649A (en)
HK (1) HK1045938A1 (en)
HR (1) HRP20010901A2 (en)
IL (1) IL146575A0 (en)
IS (1) IS6182A (en)
MX (1) MXPA01012355A (en)
NO (1) NO20015859L (en)
NZ (1) NZ515744A (en)
PE (1) PE20010212A1 (en)
PL (1) PL352575A1 (en)
RU (1) RU2001135800A (en)
SK (1) SK17012001A3 (en)
TR (1) TR200103476T2 (en)
WO (1) WO2000072870A1 (en)
ZA (1) ZA200109704B (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
AU2001268005A1 (en) 2000-07-07 2002-01-21 Lars Lannfelt Prevention and treatment of alzheimer's disease
AU1225702A (en) * 2000-09-19 2002-04-02 Evotec Neurosciences Gmbh Methods and compounds for treating brain amyloidosis
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
MY144532A (en) 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
DE10303974A1 (en) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid β (1-42) oligomers, process for their preparation and their use
TWI374893B (en) 2003-05-30 2012-10-21 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
SE0401601D0 (en) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
JP2008523815A (en) 2004-12-15 2008-07-10 エラン ファーマ インターナショナル リミテッド Humanized amyloid beta antibody for use in improving cognition
EP2289909B1 (en) 2005-11-30 2014-10-29 AbbVie Inc. Screening method, process for purifying of non-diffusible a-beta oligomers, selective antibodies against said non-diffusible a-beta oligomers and a process for manufacturing of said antibodies
PL1976877T5 (en) 2005-11-30 2017-09-29 Abbvie Inc Monoclonal antibodies against amyloid beta protein and uses thereof
NO347079B1 (en) 2006-03-23 2023-05-08 Bioarctic Neuroscience Ab Improved protofibril-selective antibodies and use thereof
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2124952A2 (en) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
PT2182983E (en) 2007-07-27 2014-09-01 Janssen Alzheimer Immunotherap Treatment of amyloidogenic diseases with humanised anti-abeta antibodies
JO3076B1 (en) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap Immunotherapy regimes dependent on apoe status
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
MX360403B (en) 2010-04-15 2018-10-31 Abbvie Inc Amyloid-beta binding proteins.
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
GB201113570D0 (en) 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
DK3166970T3 (en) 2014-07-10 2021-05-25 Bioarctic Ab IMPROVED Aß PROTOFIBRIL BINDING ANTIBODIES
CN114957438B (en) * 2022-06-28 2024-04-02 福建亿彤生物科技有限公司 Human Abeta 1-42 epitope polypeptide for detecting Alzheimer disease and preparation method thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991016819A1 (en) * 1990-04-27 1991-11-14 Molecular Rx., Inc. Method and composition for treatment of central nervous systems disease states associated with abnormal amyloid beta protein
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease

Also Published As

Publication number Publication date
PE20010212A1 (en) 2001-02-22
HRP20010901A2 (en) 2003-04-30
AU5726100A (en) 2000-12-18
KR20020016813A (en) 2002-03-06
MXPA01012355A (en) 2003-06-24
CN1353615A (en) 2002-06-12
NO20015859L (en) 2002-02-01
BG106249A (en) 2002-08-30
EE200100649A (en) 2003-02-17
CA2374897A1 (en) 2000-12-07
IS6182A (en) 2001-11-29
CZ20014150A3 (en) 2002-05-15
ZA200109704B (en) 2003-02-26
BR0011251A (en) 2002-03-05
EP1181040A1 (en) 2002-02-27
IL146575A0 (en) 2002-07-25
SK17012001A3 (en) 2002-06-04
AR024558A1 (en) 2002-10-16
NZ515744A (en) 2004-04-30
RU2001135800A (en) 2003-08-20
WO2000072870A1 (en) 2000-12-07
NO20015859D0 (en) 2001-11-30
JP2003519620A (en) 2003-06-24
HK1045938A1 (en) 2002-12-20
PL352575A1 (en) 2003-08-25

Similar Documents

Publication Publication Date Title
TR200103476T2 (en) A-beta peptide compositions and methods to prepare them
TR200401029T4 (en) Acylphenyl-urea derivatives, manufacturing methods and their use as pharmaceuticals
HK1021699A1 (en) Pentafluorobenzenesulfonamides and analogs.
AP9801378A0 (en) 9-amino-3- keto erythromycin derivatives.
BR0009610A (en) Caspase inhibitors and their use
TR199801755T2 (en) Pyrimido(5,4-D)pyrimidines, pharmaceutical substances containing these compounds.
TR200103095T2 (en) Renin blockers.
BR0215240A (en) Calcium derivatives and their use in treating diseases
TR200302242T2 (en) Pyrolopyrimidines as protein kinase inhibitors
ATE334985T1 (en) COMPOUNDS, METHODS AND PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT OF CELL DAMAGE SUCH AS DAMAGE TO NERVOUS OR VESSEL TISSUE
TR200200381T2 (en) Pyrimidine-2,4,6-Trion Metalloproteinase Inhibitors.
AP9701039A0 (en) Derivatives of 2- (2-oxo-ethlidene)-imidazolidin-4-one.
BRPI9909908B8 (en) fatty acid salt or bile acid conjugates, pharmaceutical composition comprising them and their uses
PT882049E (en) ACID 8-CYANO-1-CYCLOPROPYL-7- (2,8-DIAZABICYCLO-4,3,0-NONAN-8-YL) -6-FLUORO-1,4-DIHYDRO-4-OXO-KINOLINO-CARBOXYL- YOUR DERIVATIVES
ATE219363T1 (en) SOLUBLE PRODRUGS OF PACLITAXEL
BG103969A (en) C-4"-substituted macrolide derivatives
BR0001468A (en) hydroxycanic dioxicyclopentyl acids
BR0014355A (en) Sapogenin derivatives and their use in the treatment of cognitive dysfunction
AU8292198A (en) Inhibition of hiv-1 replication using oligocarbamate derivatives
AP9801377A0 (en) Tricyclic erythromycin derivatives.
RS91204A (en) Lyophilized and liquid preparation comprising a polysaccharide derivative of camptothecin
TR200402070T4 (en) Cyclobutene-dione derivatives and their use in the treatment of arteriosclerosis
ATE274513T1 (en) COMPOUNDS AND METHODS FOR TREATING PAIN
TR199900153T2 (en) Substituted bisindolylmaleimides to prevent cell proliferation.
YU19302A (en) 4-benzylaminoquinoline conjugates with bile acid and their heteroanalogues, methods for producing the same, medicaments containing these compounds and their use